Steady State achieve­ment [Design Issues]

posted by rajasekharkakarla – India, 2019-07-03 10:02 (455 d 02:02 ago) – Posting: # 20369
Views: 1,102

Dear All,

Greetings for the day!!!

I am designing steady state protocol for Dalfampridine Extended Release Tablets 10 mg, as per EMEA Smpc I written protocol as daily twice dosing for 5 days with 12 hours interval and 6th day only morning dose followed by PK samples.

Here my doubt is for evaluating the steady state achievement whether consideration of predose samples at morning doses is sufficient or we need to take predose samples at evening dose also.

Generally to evaluate steady state achievement we will consider at least last 3 pre-dose samples including PK sampling day.

Please help me!!!

Rajasekhar K

Edit: Category changed and subject line changed; see also this post #1, #2.
The EMEA was renamed to EMA back in 2005. There is no “EMA SmPC”, only SmPCs of the reference – which might differ between countries. [Helmut]

Complete thread:

 Admin contact
21,087 posts in 4,398 threads, 1,468 registered users;
online 38 (1 registered, 37 guests [including 5 identified bots]).
Forum time: Wednesday 12:05 CEST (Europe/Vienna)

When puzzled, it never hurts to read the primary documents 
a rather simple and self-evident principle that has, nonetheless,
completely disappeared from large sectors
of the American experience.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz